Elypta is a molecular diagnostic company focused on preventing cancer mortality by commercializing a liquid biopsy platform for earlier detection and closer monitoring. The approach is based on measurement of 19 biomarkers and use of machine learning algorithms to generate a score against cancer-type specific signatures. Studies have shown exceptional accuracy in renal cell carcinoma and the clinical development program include multiple other indications. Potential applications include early detection, differential diagnosis, surveillance of recurrence and monitoring or prediction of treatment response, replacing or complementing medical imaging. Elypta is differentiated by its pan-cancer potential, metabolism-based approach and robust, cost-efficient assay. Several years of research at Chalmers University of Technology in Gothenburg, Sweden, led to the founding of Elypta in the spring of 2017.